Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Recursion Pharmaceuticals Inc.（纳斯达克代码：RXRX）的首席执行官Christopher Gibson最近进行了一系列涉及公司A类普通股的交易。在1月8日和1月10日，Gibson总共出售了40,000股，每股价格在7.05美元至7.31美元之间。这些销售总价值为287,200美元。值得注意的是，在过去一周内，该股票下跌了约13%，目前股价为6.74美元。根据 ...

We recently published a list of 12 Cheap AI Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Recursion's share price continues to be volatile, despite its pipeline maturing and the injection of significant cash through its merger with Exscientia. While early clinical data has been ...

We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...

To get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to understand the ownership structure of the business. With 66% stake, institutions ...

Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 16,974 calls trading, 1.0x expected, and implied vol increasing over 12 ...

Shares of Recursion Pharmaceuticals Inc climbed 5.6% on Wednesday morning, reaching a three-week high as trading volumes hit ...

Recursion Pharmaceuticals, Inc. is a Salt Lake City based early to mid-stage biopharmaceutical concern focused on leveraging its supercomputing proficiency to develop therapies for rare diseases ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.6% during trading on Wednesday . The company traded as low as $7.04 and last traded at $7.02. 8,745,283 shares ...

在周二的白宫演讲中，埃里森强调了AI通过血液测试早期检测癌症的能力，以及在快速创建个性化疫苗方面的关键作用。这一宣布引发了投资者对从事AI驱动药物发现公司的兴趣，从它们股价的大幅上涨可见一斑：AbCellera Biologics上涨15%，Absi Corp上涨28%，Recursion Pharma上涨6%，Schrodinger上涨16%，Certara上涨6%。